IMG-20260906-WA0007.jpg
Interpret
analyse_media
Reading File
Searching the Web
ACR BI-RADS 4C definition malignancy probability tissue diagnosis biopsy
Searching PubMed
breast BI-RADS biopsy
Finding Sources
Finding Sources
Reading Web Page
https://cs.acr.org/-/media/ACR/Files/RADS/BI-RADS/US-Reporti…
The ultrasound report shows an abnormal, suspicious mass in the left breast:
- Location: left breast, 4 to 6 o'clock position
- Size: 20 × 29 mm (about 2 to 3 cm)
- Appearance: irregular, hypoechoic (darker than surrounding tissue) lesion with minimal internal blood flow
- BI-RADS 4C: this means high suspicion for cancer, but it is not a diagnosis. The estimated likelihood of malignancy is roughly more than 50% but less than 95%. A BI-RADS reference recommends tissue diagnosis, meaning biopsy, for this category.
- Left armpit lymph nodes: a few are enlarged and have lost the normal fatty/echogenic hilum. This is suspicious, and the radiologist has written “? metastatic nodes.” It means spread to lymph nodes is possible, but this can only be confirmed by sampling the node.
Other breast tissues, nipple/areolar area, ducts, chest muscle, and calcifications were reported as normal.
What needs to happen next
Please arrange an urgent consultation with a breast surgeon or surgical oncologist, ideally within days. The usual next step is:
- Ultrasound-guided core-needle biopsy of the breast mass.
- Needle biopsy of a suspicious left axillary lymph node, often at the same visit.
- If cancer is confirmed, pathology tests including tumor type/grade and ER, PR, and HER2 receptor testing guide treatment. Further imaging may be planned by the specialist.
An ultrasound cannot prove cancer or confirm lymph-node spread. The biopsy result is the deciding test. Do not delay evaluation, but do not assume a final diagnosis before pathology.
Is it respectable directly or should chemo be admisnistered
Reading File
Finding Sources
Finding Sources
Searching PubMed
breast neoplasms AND neoadjuvant chemotherapy
Searching the Web
ASCO guideline neoadjuvant chemotherapy breast cancer biopsy hormone receptor HER2 operable
It may be operable/resectable, but this cannot be decided from ultrasound alone. A 2.9 cm breast mass with suspicious axillary nodes is often still treatable with curative intent, but the correct order is:
- Core-needle biopsy of the breast mass
- Needle biopsy of the suspicious axillary lymph node
- Pathology testing for ER, PR, HER2, tumor grade, and type
- Breast surgeon and medical oncologist decide the treatment sequence
Do not start chemotherapy before biopsy confirmation and receptor testing.
When surgery may come first
If the tumor is confirmed cancer but is clearly removable and its biology is suitable, treatment can be:
- Surgery first, either breast-conserving surgery or mastectomy, with lymph-node assessment
- Then treatment based on pathology: radiation, hormone tablets, chemotherapy, HER2-targeted treatment, or a combination.
When chemotherapy is given before surgery
Chemotherapy before surgery, called neoadjuvant chemotherapy, may be preferred if:
- The lymph node is confirmed involved
- The cancer is triple-negative or HER2-positive
- The tumor needs shrinking to allow breast-conserving surgery
- The surgeon believes surgery first would not remove the disease adequately
For an ER/PR-positive, HER2-negative cancer in a 69-year-old, some patients may instead receive surgery first or sometimes hormone treatment before surgery. The choice depends on the biopsy and overall fitness, including heart, kidney, liver function, diabetes, and daily functional status.
So the immediate priority is a breast surgeon/surgical oncologist appointment and ultrasound-guided biopsies of both the breast lump and left axillary node. The report alone does not mean chemotherapy must start immediately.
IMG-20260908-WA0005.jpg
+2 more
Interpret and give treatment options
analyse_media
analyse_media
analyse_media
Finding Sources
Finding Sources
Searching PubMed
breast neoplasms AND neoadjuvant therapy
Searching the Web
NCI breast cancer treatment stage II stage III surgery neoadjuvant chemotherapy hormone receptor HER2
PET-CT interpretation
This scan shows a left breast cancer that appears confined to the breast and nearby regional lymph nodes, with no evidence of spread to distant organs.
Main findings
- Left breast tumor: active irregular/spiculated mass at 6 o'clock, measuring 2.4 × 1.8 × 2.8 cm.
- Skin: mild thickening over the tumor, but the chest-wall muscle is free and nipple-areola area appears normal.
- Nearby lymph nodes:
- Left level-I axillary node: 12 × 10 mm
- Left internal mammary node: 10 × 10 mm
- Both are PET-active and considered suspicious for cancer involvement.
- No distant metastases: no PET evidence of spread to lung, liver, abdomen, pelvis, bones, brain, or distant nodes.
- Other incidental points: fatty liver, osteopenia, small inactive thyroid nodules, and a minor small area of right lower-lung collapse/under-expansion. These are not described as cancer spread.
What this means
This is a serious but potentially curable, non-metastatic breast cancer situation. The favorable part of the scan is: there is no distant spread (M0).
Based on imaging alone, the breast tumor is approximately T2 because it is between 2 and 5 cm. The axillary and internal mammary nodes may mean more advanced regional nodal disease, but the final clinical stage must be decided by the breast cancer team after reviewing the biopsy report, confirming the axillary node if necessary, and completing receptor tests. Do not rely on PET-CT alone to assign a final stage.
Most likely treatment approach
Because there are suspicious axillary and internal mammary nodes, the usual approach is often treatment before surgery, but the exact treatment depends strongly on the biopsy markers.
1. Confirm all pathology before treatment
Obtain or review:
- Core biopsy report: invasive ductal carcinoma or another type, grade
- ER and PR hormone receptor status
- HER2 status
- Ki-67, if reported
- Ultrasound-guided needle/core biopsy of the suspicious left axillary node, if not already done
- A clip should be placed in any biopsied positive node before pre-operative treatment, where feasible.
2. Treatment before surgery: often preferred here
This is called neoadjuvant systemic treatment. It can shrink both breast cancer and involved lymph nodes, help plan surgery, and show how the cancer responds.
The treatment differs by subtype:
| Biopsy result | Typical pre-surgery treatment |
|---|---|
| HER2-positive | Chemotherapy plus HER2-targeted treatment, usually trastuzumab with pertuzumab |
| Triple-negative: ER-, PR-, HER2- | Chemotherapy, commonly with immunotherapy in appropriate stage II-III cases |
| ER/PR-positive, HER2-negative | Either chemotherapy before surgery or surgery first, depending on grade, node status, Ki-67/genomic risk, and fitness. In a postmenopausal woman, hormone therapy before surgery can sometimes be considered if chemotherapy is unsuitable or the cancer is strongly hormone-sensitive. |
Guidelines use tumor stage, grade, and ER/PR/HER2 results to decide whether pre-operative treatment is appropriate. ASCO neoadjuvant-treatment guidance supports pre-operative systemic therapy particularly when it will guide later treatment or reduce disease before surgery.
3. Surgery after systemic treatment
After response assessment, the surgeon may recommend:
- Breast-conserving surgery (lumpectomy) if the tumor can be safely removed with clear margins and acceptable breast appearance, or
- Mastectomy if breast conservation is not suitable or is not preferred.
The axilla will also be managed surgically. The method depends on whether the axillary node biopsy is positive before treatment and how well nodes respond. This may include targeted sentinel-node surgery or axillary dissection.
4. Radiation treatment
Radiotherapy is very likely after breast-conserving surgery, and may also be needed after mastectomy because of suspicious regional nodes. It commonly covers the breast/chest wall and selected regional nodes, including the internal mammary region when indicated.
5. Treatment after surgery
This is based on final pathology and response:
- Hormone tablets for ER/PR-positive cancer, commonly an aromatase inhibitor in postmenopausal women
- Completion or adjustment of HER2-targeted treatment for HER2-positive cancer
- Additional chemotherapy or other systemic treatment in selected cases with residual disease
- Bone-health assessment and treatment if required, especially because the report notes osteopenia and aromatase inhibitors can reduce bone density.
Immediate practical next steps
- See the breast surgical oncologist and medical oncologist together, preferably through a multidisciplinary breast clinic.
- Take the PET-CT report, ultrasound report, biopsy slides/blocks, and pathology report.
- Confirm whether the axillary node has been biopsied and clipped.
- Ask for the written ER, PR, HER2, grade, and Ki-67 results.
- Have diabetes/glucose assessed and controlled. The PET scan glucose was 208 mg/dL, which is high and should be addressed before chemotherapy or surgery.
Bottom line
This scan does not show stage-IV distant metastatic disease. It suggests breast cancer with nearby lymph-node involvement, so treatment should be planned with curative intent. Given the nodal findings, chemotherapy or other systemic treatment before surgery is quite possible and may be preferred, but the final choice cannot be made without the biopsy receptor results.
What types it can be and how can be the treatment options for them fnac showed ductal carcinoma
Reading File
Finding Sources
Finding Sources
Finding Sources
Searching PubMed
breast cancer subtype neoadjuvant therapy
Searching the Web
NCI invasive ductal carcinoma ER PR HER2 breast cancer treatment types
FNAC showing ductal carcinoma usually means cancer arising from the milk ducts. Given the PET-CT shows suspicious axillary and internal mammary lymph nodes, this is more likely invasive ductal carcinoma (IDC) rather than DCIS alone. However, confirm the exact wording on the FNAC or preferably a core-needle biopsy report.
The PET-CT is encouraging in one important respect: it shows no distant spread to liver, lungs, bones, or other organs. This is usually approached with curative-intent treatment.
The types that matter most
“Ductal carcinoma” describes where it started. The treatment is mainly determined by three tests on the tumor:
- ER: estrogen receptor
- PR: progesterone receptor
- HER2
- Also important: tumor grade and Ki-67 proliferation index
Ask for a core-biopsy pathology report including: invasive type, grade, ER %, PR %, HER2 IHC score and, if needed, HER2 FISH/ISH result, Ki-67. FNAC alone may not provide all this information adequately.
1. Hormone-receptor positive, HER2-negative
ER and/or PR positive; HER2 negative. This is common, especially after menopause.
Possible treatment plan
- Either surgery first or treatment before surgery, depending on grade and nodal status
- If chemotherapy is needed: chemotherapy before or after surgery
- Surgery: lumpectomy if feasible, or mastectomy
- Radiotherapy, especially with lymph-node involvement
- Long-term hormone treatment, usually an aromatase inhibitor such as anastrozole, letrozole, or exemestane in postmenopausal women
- In some higher-risk node-positive cases, additional targeted tablets may be considered after surgery
For a strongly ER-positive, lower-grade tumor in a 69-year-old, doctors sometimes use hormone treatment before surgery when chemotherapy is less suitable. This is different from chemotherapy and is generally better tolerated, though it works more slowly.
2. HER2-positive breast cancer
HER2 positive, whether hormone receptors are positive or negative.
Possible treatment plan
- Usually chemotherapy plus HER2-targeted injections before surgery, commonly trastuzumab and pertuzumab with chemotherapy
- Surgery after the tumor and nodes have responded
- Radiation
- Continued HER2-targeted treatment after surgery, commonly completing about a year in total
- If ER/PR-positive too, hormone tablets are also added
For a tumor about 2.8 cm with suspicious lymph nodes, pre-operative therapy is commonly favored in HER2-positive disease. NCI guidance on breast-cancer biomarkers explains that HER2 and hormone-receptor results determine the cancer category and systemic treatment.
3. Triple-negative breast cancer
ER negative, PR negative, HER2 negative.
Possible treatment plan
- Usually chemotherapy before surgery
- For stage II or III disease, immunotherapy with pembrolizumab plus chemotherapy may be considered, followed by surgery and continuation of immunotherapy in eligible patients
- Surgery
- Radiation
- If cancer remains at surgery, further treatment may be recommended based on pathology and genetic testing
This subtype does not respond to hormone tablets or HER2-targeted drugs, so chemotherapy is usually more central. A recent systematic review supports the role of neoadjuvant immune checkpoint therapy in appropriate triple-negative disease (PMID: 40213551).
4. Hormone-receptor positive and HER2-positive
ER and/or PR positive plus HER2 positive.
Possible treatment plan
- Chemotherapy plus trastuzumab/pertuzumab before surgery is often used for node-positive or larger tumors
- Surgery
- Radiation
- Continue HER2 treatment
- Add hormone therapy for several years
What the PET-CT suggests for her specifically
- Tumor: roughly 2.8 cm, left breast
- Suspected regional nodes: left axillary and internal mammary nodes
- No distant metastasis: M0 on PET-CT
Therefore, chemotherapy before surgery may be recommended, particularly if the tumor is HER2-positive or triple-negative, or if the axillary node is confirmed positive. But it is not automatic for every ductal carcinoma.
Likely overall sequence
- Core biopsy review with ER, PR, HER2, grade, and Ki-67
- Core biopsy of the left axillary node, if not already confirmed. Ideally, a marker clip is placed in a positive node before treatment.
- Medical oncologist decides between:
- chemotherapy before surgery
- HER2-targeted therapy plus chemotherapy before surgery
- hormone treatment before surgery in selected ER-positive cases
- surgery first in selected ER-positive/HER2-negative cases
- Surgery: breast-conserving surgery or mastectomy, plus appropriate axillary-node surgery
- Radiotherapy: likely needed because of suspected nodal involvement
- Post-surgery treatment tailored to final pathology and response
Key message
Do not choose chemo versus direct surgery based only on the word “ductal carcinoma.” The deciding report is the receptor profile:
- HER2-positive: usually chemotherapy + HER2 injections before surgery
- Triple-negative: usually chemotherapy, often with immunotherapy, before surgery
- ER/PR-positive, HER2-negative: surgery first, chemotherapy first, or hormone treatment first may each be appropriate depending on grade, node biopsy, Ki-67, and her overall health
Please share the FNAC or core-biopsy report, especially the ER, PR, HER2, grade, and Ki-67 results, and I can explain the likely treatment pathway more specifically.
How many cycles of chemo needed before surgery in every case
Reading File
Finding Sources
Searching PubMed
breast cancer neoadjuvant chemotherapy regimen cycles
Searching the Web
ASCO neoadjuvant breast cancer chemotherapy regimen cycles HER2 positive triple negative
There is no single number of chemotherapy cycles for every ductal carcinoma. It depends mainly on ER, PR, HER2 status, lymph-node biopsy, grade, heart/kidney/liver function, diabetes control, and how well she tolerates treatment.
For this case, because the tumor is about 2.8 cm and PET-CT suggests regional lymph nodes but no distant spread, pre-surgery treatment is often considered, especially for HER2-positive or triple-negative disease.
Typical treatment before surgery
| Cancer subtype from core biopsy | Usual treatment before surgery | Typical duration/cycles |
|---|---|---|
| HER2-positive | Chemotherapy plus trastuzumab and pertuzumab | Often 6 cycles, every 3 weeks, about 18 weeks. Some plans use 8 cycles over about 5 months. |
| Triple-negative | Chemotherapy, often combined with pembrolizumab immunotherapy for stage II-III disease | Commonly 8 chemotherapy cycles over about 5 to 6 months: 4 cycles of taxane/carboplatin, then 4 cycles of AC or EC. Pembrolizumab is usually continued after surgery if started before surgery. |
| ER/PR-positive, HER2-negative, high-grade or confirmed node-positive | Chemotherapy may be used before surgery | Often 6 to 8 cycles over about 4 to 5 months, depending on regimen. |
| ER/PR-positive, HER2-negative, strongly hormone-sensitive/lower-grade | Often surgery first, rather than chemo first. In selected postmenopausal patients, hormone therapy can be used before surgery | No chemo in some cases. Hormone therapy may be given for roughly 4 to 6 months, sometimes longer, to shrink/control the tumor before surgery. |
Common examples
If HER2-positive
A frequently used option is TCHP:
- Docetaxel + carboplatin + trastuzumab + pertuzumab
- 6 cycles, once every 3 weeks
- Surgery follows
- Trastuzumab, with or without pertuzumab, usually continues afterward to complete about 1 year of anti-HER2 therapy.
If triple-negative
A common modern plan is:
- Paclitaxel + carboplatin for 4 cycles with pembrolizumab
- Then doxorubicin/cyclophosphamide or epirubicin/cyclophosphamide for 4 cycles with pembrolizumab
- Total: 8 chemotherapy cycles before surgery
- Then surgery, radiation, and often further pembrolizumab if it was started.
If hormone-positive, HER2-negative
There are several valid paths:
- Surgery first, then decide whether chemotherapy is useful based on final pathology, nodal status, and sometimes a genomic test.
- Or 4 to 8 chemotherapy cycles before surgery if the cancer is high-grade, rapidly growing, or lymph-node-positive.
- Or, for a strongly ER-positive cancer in a 69-year-old where chemotherapy is less suitable, an aromatase-inhibitor hormone tablet such as letrozole, anastrozole, or exemestane may be used before surgery. This is not chemotherapy.
For her specifically
Because she has suspected axillary and internal mammary node involvement, doctors may lean toward treatment before surgery. But the plan should not be finalized until the core biopsy gives ER, PR, HER2, grade, and ideally Ki-67.
- If HER2-positive: likely about 6 cycles before surgery.
- If triple-negative: often about 8 cycles before surgery.
- If ER/PR-positive and HER2-negative: could be direct surgery, 4 to 8 chemo cycles, or hormone therapy first. The receptor profile and grade decide this.
The number can be shortened, delayed, or doses reduced if blood counts, infection, neuropathy, heart function, or other health issues make it unsafe. It should not be changed merely because the lump shrinks early unless the oncologist has a specific reason.
Before treatment, ask the oncologist these exact questions:
- What are the ER, PR, HER2, grade, and Ki-67 results?
- Has the axillary node been biopsy-confirmed and clipped?
- Is the recommended plan surgery first, chemotherapy first, or hormone therapy first, and why?
- What exact regimen is planned, how many cycles, and how many weeks?
- Is an echocardiogram needed before treatment? This is especially important if HER2-targeted treatment or certain chemotherapy drugs are planned.
- How will the high blood sugar noted on PET-CT be controlled during treatment?
The NCI overview of stages I-III breast cancer treatment notes that chemotherapy is more likely when tumors are high grade, node-positive, HER2-positive, or triple-negative.
+10 more
Interpret and give the treatment plan
The reports identify the tumor subtype and outline a likely treatment pathway, but the exact order of treatment needs a multidisciplinary cancer-team decision.
Asking for Preferences
Which part should I explain in detail next?
The ultrasound report shows an abnormal, suspicious mass in the left breast:
- Location: left breast, 4 to 6 o'clock position
- Size: 20 × 29 mm (about 2 to 3 cm)
- Appearance: irregular, hypoechoic (darker than surrounding tissue) lesion with minimal internal blood flow
- BI-RADS 4C: this means high suspicion for cancer, but it is not a diagnosis. The estimated likelihood of malignancy is roughly more than 50% but less than 95%. A BI-RADS reference recommends tissue diagnosis, meaning biopsy, for this category.
- Left armpit lymph nodes: a few are enlarged and have lost the normal fatty/echogenic hilum. This is suspicious, and the radiologist has written “? metastatic nodes.” It means spread to lymph nodes is possible, but this can only be confirmed by sampling the node.
Other breast tissues, nipple/areolar area, ducts, chest muscle, and calcifications were reported as normal.
What needs to happen next
Please arrange an urgent consultation with a breast surgeon or surgical oncologist, ideally within days. The usual next step is:
- Ultrasound-guided core-needle biopsy of the breast mass.
- Needle biopsy of a suspicious left axillary lymph node, often at the same visit.
- If cancer is confirmed, pathology tests including tumor type/grade and ER, PR, and HER2 receptor testing guide treatment. Further imaging may be planned by the specialist.
An ultrasound cannot prove cancer or confirm lymph-node spread. The biopsy result is the deciding test. Do not delay evaluation, but do not assume a final diagnosis before pathology.It may be operable/resectable, but this cannot be decided from ultrasound alone. A 2.9 cm breast mass with suspicious axillary nodes is often still treatable with curative intent, but the correct order is:
- Core-needle biopsy of the breast mass
- Needle biopsy of the suspicious axillary lymph node
- Pathology testing for ER, PR, HER2, tumor grade, and type
- Breast surgeon and medical oncologist decide the treatment sequence
Do not start chemotherapy before biopsy confirmation and receptor testing.
When surgery may come first
If the tumor is confirmed cancer but is clearly removable and its biology is suitable, treatment can be:
- Surgery first, either breast-conserving surgery or mastectomy, with lymph-node assessment
- Then treatment based on pathology: radiation, hormone tablets, chemotherapy, HER2-targeted treatment, or a combination.
When chemotherapy is given before surgery
Chemotherapy before surgery, called neoadjuvant chemotherapy, may be preferred if:
- The lymph node is confirmed involved
- The cancer is triple-negative or HER2-positive
- The tumor needs shrinking to allow breast-conserving surgery
- The surgeon believes surgery first would not remove the disease adequately
For an ER/PR-positive, HER2-negative cancer in a 69-year-old, some patients may instead receive surgery first or sometimes hormone treatment before surgery. The choice depends on the biopsy and overall fitness, including heart, kidney, liver function, diabetes, and daily functional status.
So the immediate priority is a breast surgeon/surgical oncologist appointment and ultrasound-guided biopsies of both the breast lump and left axillary node. The report alone does not mean chemotherapy must start immediately.## PET-CT interpretation
This scan shows a left breast cancer that appears confined to the breast and nearby regional lymph nodes, with no evidence of spread to distant organs.
Main findings
- Left breast tumor: active irregular/spiculated mass at 6 o'clock, measuring 2.4 × 1.8 × 2.8 cm.
- Skin: mild thickening over the tumor, but the chest-wall muscle is free and nipple-areola area appears normal.
- Nearby lymph nodes:
- Left level-I axillary node: 12 × 10 mm
- Left internal mammary node: 10 × 10 mm
- Both are PET-active and considered suspicious for cancer involvement.
- No distant metastases: no PET evidence of spread to lung, liver, abdomen, pelvis, bones, brain, or distant nodes.
- Other incidental points: fatty liver, osteopenia, small inactive thyroid nodules, and a minor small area of right lower-lung collapse/under-expansion. These are not described as cancer spread.
What this means
This is a serious but potentially curable, non-metastatic breast cancer situation. The favorable part of the scan is: there is no distant spread (M0).
Based on imaging alone, the breast tumor is approximately T2 because it is between 2 and 5 cm. The axillary and internal mammary nodes may mean more advanced regional nodal disease, but the final clinical stage must be decided by the breast cancer team after reviewing the biopsy report, confirming the axillary node if necessary, and completing receptor tests. Do not rely on PET-CT alone to assign a final stage.
Most likely treatment approach
Because there are suspicious axillary and internal mammary nodes, the usual approach is often treatment before surgery, but the exact treatment depends strongly on the biopsy markers.
1. Confirm all pathology before treatment
Obtain or review:
- Core biopsy report: invasive ductal carcinoma or another type, grade
- ER and PR hormone receptor status
- HER2 status
- Ki-67, if reported
- Ultrasound-guided needle/core biopsy of the suspicious left axillary node, if not already done
- A clip should be placed in any biopsied positive node before pre-operative treatment, where feasible.
2. Treatment before surgery: often preferred here
This is called neoadjuvant systemic treatment. It can shrink both breast cancer and involved lymph nodes, help plan surgery, and show how the cancer responds.
The treatment differs by subtype:
| Biopsy result | Typical pre-surgery treatment |
|---|---|
| HER2-positive | Chemotherapy plus HER2-targeted treatment, usually trastuzumab with pertuzumab |
| Triple-negative: ER-, PR-, HER2- | Chemotherapy, commonly with immunotherapy in appropriate stage II-III cases |
| ER/PR-positive, HER2-negative | Either chemotherapy before surgery or surgery first, depending on grade, node status, Ki-67/genomic risk, and fitness. In a postmenopausal woman, hormone therapy before surgery can sometimes be considered if chemotherapy is unsuitable or the cancer is strongly hormone-sensitive. |
Guidelines use tumor stage, grade, and ER/PR/HER2 results to decide whether pre-operative treatment is appropriate. ASCO neoadjuvant-treatment guidance supports pre-operative systemic therapy particularly when it will guide later treatment or reduce disease before surgery.
3. Surgery after systemic treatment
After response assessment, the surgeon may recommend:
- Breast-conserving surgery (lumpectomy) if the tumor can be safely removed with clear margins and acceptable breast appearance, or
- Mastectomy if breast conservation is not suitable or is not preferred.
The axilla will also be managed surgically. The method depends on whether the axillary node biopsy is positive before treatment and how well nodes respond. This may include targeted sentinel-node surgery or axillary dissection.
4. Radiation treatment
Radiotherapy is very likely after breast-conserving surgery, and may also be needed after mastectomy because of suspicious regional nodes. It commonly covers the breast/chest wall and selected regional nodes, including the internal mammary region when indicated.
5. Treatment after surgery
This is based on final pathology and response:
- Hormone tablets for ER/PR-positive cancer, commonly an aromatase inhibitor in postmenopausal women
- Completion or adjustment of HER2-targeted treatment for HER2-positive cancer
- Additional chemotherapy or other systemic treatment in selected cases with residual disease
- Bone-health assessment and treatment if required, especially because the report notes osteopenia and aromatase inhibitors can reduce bone density.
Immediate practical next steps
- See the breast surgical oncologist and medical oncologist together, preferably through a multidisciplinary breast clinic.
- Take the PET-CT report, ultrasound report, biopsy slides/blocks, and pathology report.
- Confirm whether the axillary node has been biopsied and clipped.
- Ask for the written ER, PR, HER2, grade, and Ki-67 results.
- Have diabetes/glucose assessed and controlled. The PET scan glucose was 208 mg/dL, which is high and should be addressed before chemotherapy or surgery.
Bottom line
This scan does not show stage-IV distant metastatic disease. It suggests breast cancer with nearby lymph-node involvement, so treatment should be planned with curative intent. Given the nodal findings, chemotherapy or other systemic treatment before surgery is quite possible and may be preferred, but the final choice cannot be made without the biopsy receptor results.FNAC showing ductal carcinoma usually means cancer arising from the milk ducts. Given the PET-CT shows suspicious axillary and internal mammary lymph nodes, this is more likely invasive ductal carcinoma (IDC) rather than DCIS alone. However, confirm the exact wording on the FNAC or preferably a core-needle biopsy report.
The PET-CT is encouraging in one important respect: it shows no distant spread to liver, lungs, bones, or other organs. This is usually approached with curative-intent treatment.
The types that matter most
“Ductal carcinoma” describes where it started. The treatment is mainly determined by three tests on the tumor:
- ER: estrogen receptor
- PR: progesterone receptor
- HER2
- Also important: tumor grade and Ki-67 proliferation index
Ask for a core-biopsy pathology report including: invasive type, grade, ER %, PR %, HER2 IHC score and, if needed, HER2 FISH/ISH result, Ki-67. FNAC alone may not provide all this information adequately.
1. Hormone-receptor positive, HER2-negative
ER and/or PR positive; HER2 negative. This is common, especially after menopause.
Possible treatment plan
- Either surgery first or treatment before surgery, depending on grade and nodal status
- If chemotherapy is needed: chemotherapy before or after surgery
- Surgery: lumpectomy if feasible, or mastectomy
- Radiotherapy, especially with lymph-node involvement
- Long-term hormone treatment, usually an aromatase inhibitor such as anastrozole, letrozole, or exemestane in postmenopausal women
- In some higher-risk node-positive cases, additional targeted tablets may be considered after surgery
For a strongly ER-positive, lower-grade tumor in a 69-year-old, doctors sometimes use hormone treatment before surgery when chemotherapy is less suitable. This is different from chemotherapy and is generally better tolerated, though it works more slowly.
2. HER2-positive breast cancer
HER2 positive, whether hormone receptors are positive or negative.
Possible treatment plan
- Usually chemotherapy plus HER2-targeted injections before surgery, commonly trastuzumab and pertuzumab with chemotherapy
- Surgery after the tumor and nodes have responded
- Radiation
- Continued HER2-targeted treatment after surgery, commonly completing about a year in total
- If ER/PR-positive too, hormone tablets are also added
For a tumor about 2.8 cm with suspicious lymph nodes, pre-operative therapy is commonly favored in HER2-positive disease. NCI guidance on breast-cancer biomarkers explains that HER2 and hormone-receptor results determine the cancer category and systemic treatment.
3. Triple-negative breast cancer
ER negative, PR negative, HER2 negative.
Possible treatment plan
- Usually chemotherapy before surgery
- For stage II or III disease, immunotherapy with pembrolizumab plus chemotherapy may be considered, followed by surgery and continuation of immunotherapy in eligible patients
- Surgery
- Radiation
- If cancer remains at surgery, further treatment may be recommended based on pathology and genetic testing
This subtype does not respond to hormone tablets or HER2-targeted drugs, so chemotherapy is usually more central. A recent systematic review supports the role of neoadjuvant immune checkpoint therapy in appropriate triple-negative disease (PMID: 40213551).
4. Hormone-receptor positive and HER2-positive
ER and/or PR positive plus HER2 positive.
Possible treatment plan
- Chemotherapy plus trastuzumab/pertuzumab before surgery is often used for node-positive or larger tumors
- Surgery
- Radiation
- Continue HER2 treatment
- Add hormone therapy for several years
What the PET-CT suggests for her specifically
- Tumor: roughly 2.8 cm, left breast
- Suspected regional nodes: left axillary and internal mammary nodes
- No distant metastasis: M0 on PET-CT
Therefore, chemotherapy before surgery may be recommended, particularly if the tumor is HER2-positive or triple-negative, or if the axillary node is confirmed positive. But it is not automatic for every ductal carcinoma.
Likely overall sequence
- Core biopsy review with ER, PR, HER2, grade, and Ki-67
- Core biopsy of the left axillary node, if not already confirmed. Ideally, a marker clip is placed in a positive node before treatment.
- Medical oncologist decides between:
- chemotherapy before surgery
- HER2-targeted therapy plus chemotherapy before surgery
- hormone treatment before surgery in selected ER-positive cases
- surgery first in selected ER-positive/HER2-negative cases
- Surgery: breast-conserving surgery or mastectomy, plus appropriate axillary-node surgery
- Radiotherapy: likely needed because of suspected nodal involvement
- Post-surgery treatment tailored to final pathology and response
Key message
Do not choose chemo versus direct surgery based only on the word “ductal carcinoma.” The deciding report is the receptor profile:
- HER2-positive: usually chemotherapy + HER2 injections before surgery
- Triple-negative: usually chemotherapy, often with immunotherapy, before surgery
- ER/PR-positive, HER2-negative: surgery first, chemotherapy first, or hormone treatment first may each be appropriate depending on grade, node biopsy, Ki-67, and her overall health
Please share the FNAC or core-biopsy report, especially the ER, PR, HER2, grade, and Ki-67 results, and I can explain the likely treatment pathway more specifically.There is no single number of chemotherapy cycles for every ductal carcinoma. It depends mainly on ER, PR, HER2 status, lymph-node biopsy, grade, heart/kidney/liver function, diabetes control, and how well she tolerates treatment.
For this case, because the tumor is about 2.8 cm and PET-CT suggests regional lymph nodes but no distant spread, pre-surgery treatment is often considered, especially for HER2-positive or triple-negative disease.
Typical treatment before surgery
| Cancer subtype from core biopsy | Usual treatment before surgery | Typical duration/cycles |
|---|---|---|
| HER2-positive | Chemotherapy plus trastuzumab and pertuzumab | Often 6 cycles, every 3 weeks, about 18 weeks. Some plans use 8 cycles over about 5 months. |
| Triple-negative | Chemotherapy, often combined with pembrolizumab immunotherapy for stage II-III disease | Commonly 8 chemotherapy cycles over about 5 to 6 months: 4 cycles of taxane/carboplatin, then 4 cycles of AC or EC. Pembrolizumab is usually continued after surgery if started before surgery. |
| ER/PR-positive, HER2-negative, high-grade or confirmed node-positive | Chemotherapy may be used before surgery | Often 6 to 8 cycles over about 4 to 5 months, depending on regimen. |
| ER/PR-positive, HER2-negative, strongly hormone-sensitive/lower-grade | Often surgery first, rather than chemo first. In selected postmenopausal patients, hormone therapy can be used before surgery | No chemo in some cases. Hormone therapy may be given for roughly 4 to 6 months, sometimes longer, to shrink/control the tumor before surgery. |
Common examples
If HER2-positive
A frequently used option is TCHP:
- Docetaxel + carboplatin + trastuzumab + pertuzumab
- 6 cycles, once every 3 weeks
- Surgery follows
- Trastuzumab, with or without pertuzumab, usually continues afterward to complete about 1 year of anti-HER2 therapy.
If triple-negative
A common modern plan is:
- Paclitaxel + carboplatin for 4 cycles with pembrolizumab
- Then doxorubicin/cyclophosphamide or epirubicin/cyclophosphamide for 4 cycles with pembrolizumab
- Total: 8 chemotherapy cycles before surgery
- Then surgery, radiation, and often further pembrolizumab if it was started.
If hormone-positive, HER2-negative
There are several valid paths:
- Surgery first, then decide whether chemotherapy is useful based on final pathology, nodal status, and sometimes a genomic test.
- Or 4 to 8 chemotherapy cycles before surgery if the cancer is high-grade, rapidly growing, or lymph-node-positive.
- Or, for a strongly ER-positive cancer in a 69-year-old where chemotherapy is less suitable, an aromatase-inhibitor hormone tablet such as letrozole, anastrozole, or exemestane may be used before surgery. This is not chemotherapy.
For her specifically
Because she has suspected axillary and internal mammary node involvement, doctors may lean toward treatment before surgery. But the plan should not be finalized until the core biopsy gives ER, PR, HER2, grade, and ideally Ki-67.
- If HER2-positive: likely about 6 cycles before surgery.
- If triple-negative: often about 8 cycles before surgery.
- If ER/PR-positive and HER2-negative: could be direct surgery, 4 to 8 chemo cycles, or hormone therapy first. The receptor profile and grade decide this.
The number can be shortened, delayed, or doses reduced if blood counts, infection, neuropathy, heart function, or other health issues make it unsafe. It should not be changed merely because the lump shrinks early unless the oncologist has a specific reason.
Before treatment, ask the oncologist these exact questions:
- What are the ER, PR, HER2, grade, and Ki-67 results?
- Has the axillary node been biopsy-confirmed and clipped?
- Is the recommended plan surgery first, chemotherapy first, or hormone therapy first, and why?
- What exact regimen is planned, how many cycles, and how many weeks?
- Is an echocardiogram needed before treatment? This is especially important if HER2-targeted treatment or certain chemotherapy drugs are planned.
- How will the high blood sugar noted on PET-CT be controlled during treatment?
The NCI overview of stages I-III breast cancer treatment notes that chemotherapy is more likely when tumors are high grade, node-positive, HER2-positive, or triple-negative.The reports identify the tumor subtype and outline a likely treatment pathway, but the exact order of treatment needs a multidisciplinary cancer-team decision.
Finding Sources
Finding Sources
Finding Sources
Searching PubMed
HER2 positive breast cancer neoadjuvant trastuzumab pertuzumab
Searching the Web
NCI HER2-positive early breast cancer treatment neoadjuvant trastuzumab pertuzumab surgery radiation endocrine therapy
Final diagnosis from the biopsy
This is:
- Invasive ductal carcinoma, no special type (IDC-NST) of the left breast
- Grade 3 cancer, meaning high-grade and faster-growing under the microscope
- Modified Bloom-Richardson score: 8/9
- ER positive: 15% cells, Allred 5/8
- PR positive: 15% cells, Allred 5/8
- HER2 strongly positive: IHC 3+, staining in 90% of invasive cancer cells
- Ki-67: 20%, an intermediate proliferation marker
- PET-CT: tumor about 2.8 cm, suspicious left axillary and internal mammary lymph nodes, but no distant metastasis.
This is HER2-positive, hormone-receptor-positive invasive breast cancer, not triple-negative breast cancer. It is a treatable, non-metastatic cancer and treatment should be with curative intent.
What the doctor’s note appears to say
The handwritten note correctly identifies:
- IDC grade 3
- ER/PR positive
- HER2 3+ positive
- A proposed plan for left mastectomy with axillary clearance
It also mentions pre-operative testing:
- Major surgical profile with 2D echo
- PAC, meaning pre-anaesthetic check-up
The echocardiogram is important because HER2-targeted medicines can occasionally affect heart pumping function.
Usual preferred treatment sequence in this situation
Because the cancer is:
- HER2-positive
- Around 2.8 cm
- Grade 3
- Has suspected nearby lymph-node involvement
many breast oncology teams would usually discuss treatment before surgery, called neoadjuvant therapy:
Step 1: Treatment before surgery
A common regimen is TCHP, given once every 3 weeks for 6 cycles:
- T: docetaxel chemotherapy
- C: carboplatin chemotherapy
- H: trastuzumab, anti-HER2 targeted therapy
- P: pertuzumab, anti-HER2 targeted therapy
This takes about 18 weeks, or around 4 to 5 months.
The intention is to:
- Shrink the breast tumor
- Treat microscopic cancer cells early
- Reduce cancer in the axillary nodes
- Show how responsive the cancer is
- Guide the best medicine after surgery
For node-positive or high-risk HER2-positive cancers, trastuzumab plus pertuzumab with chemotherapy before surgery is widely used. A recent systematic review also supports dual HER2 blockade in this setting.
Step 2: Surgery
After pre-operative treatment and reassessment, surgery is performed.
Options include:
- Breast-conserving surgery if there is a strong response and it can be safely done with clear margins, or
- Mastectomy, which is already proposed by the surgeon.
The axillary approach should be based on whether a node is confirmed positive before treatment and the response to treatment. If possible, ask whether the suspicious axillary node should be core-biopsied and clipped before chemotherapy. This improves planning of later node surgery.
Step 3: Radiation therapy
Radiation is likely because PET-CT suggests regional lymph-node involvement, including an internal mammary node.
After mastectomy, it may include:
- Chest wall
- Supraclavicular/axillary nodal areas
- Internal mammary nodal region
Radiation to these areas is commonly considered for high-risk or node-positive cases. Sabiston Textbook of Surgery, section “Radiation Therapy for Breast Cancer,” notes that regional nodal radiation can include axillary, supraclavicular, and internal mammary nodes.
Step 4: Continue HER2-targeted treatment
After surgery:
- If there is no invasive cancer remaining in breast and nodes: usually continue trastuzumab, sometimes with pertuzumab, to complete about one year total of HER2-directed treatment.
- If cancer remains in breast or nodes after pre-operative treatment: doctors often switch to trastuzumab emtansine (T-DM1) after surgery, usually for 14 cycles, because residual disease indicates higher recurrence risk.
Step 5: Hormone treatment
Because ER and PR are positive, she will also need hormone-blocking treatment after completion of chemotherapy, usually alongside or after radiation as directed.
For a 69-year-old postmenopausal woman, this is commonly:
- Letrozole, anastrozole, or exemestane
- Usually for at least 5 years, sometimes longer depending on final nodal status and tolerance.
The ER/PR positivity is only 15%, but it is still clinically positive. Hormone therapy is likely to offer benefit, although HER2-targeted therapy and chemotherapy are the more immediate priorities.
Is direct mastectomy first wrong?
Not necessarily. The tumor appears surgically removable, and direct mastectomy plus axillary surgery is a possible route.
However, with a >2 cm, grade 3, HER2 3+ tumor and suspected lymph nodes, it is reasonable and important to ask for a medical oncology opinion before proceeding directly to surgery. Many multidisciplinary teams would favor 6 cycles of TCHP first, then surgery, because this cancer subtype often responds very well to HER2-targeted pre-operative treatment.
A practical question for the team is:
“Since this is a 2.8 cm grade-3 HER2 3+ cancer with PET-suspicious axillary/internal mammary nodes, should we receive six cycles of TCHP before mastectomy rather than operate first? If not, what clinical reason favors surgery first?”
Immediate checklist
Before choosing the final sequence:
- Medical oncologist consultation, ideally before surgery.
- Review PET-CT and pathology at a breast-cancer multidisciplinary meeting.
- 2D echocardiogram before trastuzumab/pertuzumab or anthracycline-containing chemotherapy.
- CBC, kidney function, liver tests, blood sugar/HbA1c, hepatitis B screening, and other pre-chemotherapy testing.
- Strongly consider biopsy of the left axillary node, with clip placement if positive, if this has not yet been done.
- Discuss diabetes control. The PET-CT glucose was 208 mg/dL, and good glucose control lowers infection and wound-healing risks during chemotherapy and surgery.
- Discuss bone health, because osteopenia is present and future aromatase-inhibitor treatment can reduce bone density.
Bottom line
The most likely evidence-based plan is:
6 cycles TCHP before surgery → left breast surgery with appropriate node surgery → radiation to chest wall/regional nodes → complete HER2 treatment to one year → hormone tablets for at least 5 years.
Direct mastectomy first can be considered, but given the HER2-positive biology and suspicious nodes, obtain a medical-oncology or multidisciplinary opinion about neoadjuvant TCHP first before finalizing surgery.
What is allred score and explain this situation
Reading File
Finding Sources
Finding Sources
Searching PubMed
Allred score estrogen receptor breast cancer
Searching the Web
ASCO CAP breast cancer ER low positive 1% 10% Allred score HER2 positive treatment
What is the Allred score?
The Allred score is a way pathologists report how strongly breast-cancer cells test positive for estrogen receptors (ER) or progesterone receptors (PR).
It combines two parts:
- Proportion score (0 to 5): percentage of cancer cells that stain positive
- Intensity score (0 to 3): how weak, moderate, or strong the staining is
Total = 0 to 8
| Total Allred score | Meaning |
|---|---|
| 0-2 | Negative |
| 3-8 | Positive |
Her results
- ER: Allred 5/8 = proportion 3 + intensity 2
- PR: Allred 5/8 = proportion 3 + intensity 2
- About 15% of tumor cells are positive for ER and PR, with moderate staining.
So the cancer is hormone-receptor positive. It is not strongly hormone-driven like a tumor with 80-100% ER positivity, but hormone treatment should still be part of her treatment after the main treatment. Current guidance generally considers tumors with at least 1% ER staining eligible for endocrine treatment, although the benefit is less certain in the 1-10% “ER-low” range. Her result is 15%, so it is above that ER-low category. See the CAP overview of ER-low testing.
Explanation of her complete situation
She has:
- Invasive ductal carcinoma, no special type, left breast
This means the cancer has invaded out of the milk duct into breast tissue. - Grade 3, score 8/9
The cells look more abnormal and tend to behave more aggressively than grade 1 or 2 cancers. - HER2 IHC 3+ positive in 90% of cancer cells
This is a definite HER2-positive cancer. No additional HER2 FISH test is usually required for an IHC 3+ result. - ER and PR positive at 15%
Hormone therapy is expected to be useful, but HER2-directed therapy is especially important. - Ki-67 20%
This indicates a moderate rate of cell division. Grade 3 and HER2 positivity are more important factors in deciding immediate treatment. - PET-CT shows a roughly 2.8 cm breast tumor and suspicious lymph nodes in the left armpit and internal mammary area.
- No distant spread is seen in the PET-CT. No liver, lung, bone, abdominal, or distant-node metastasis was identified.
In plain language
This is a high-risk but treatable, non-metastatic breast cancer. It is not stage IV based on the scan. The nearby nodes may contain cancer, but that is regional spread and can still be treated with the goal of cure.
HER2 positivity makes the cancer more active, but it also gives doctors a very effective treatment target. Anti-HER2 medicines such as trastuzumab and pertuzumab significantly improve outcomes in this subtype.
Why chemotherapy before surgery is being considered
Her combination of features makes pre-operative treatment reasonable:
- tumor is over 2 cm
- grade 3
- HER2 positive
- PET-suspicious regional lymph nodes
For many patients like this, the preferred sequence is:
1. Before surgery: chemotherapy plus HER2-targeted treatment
A commonly used plan is TCHP, every 3 weeks for 6 cycles:
- T: docetaxel
- C: carboplatin
- H: trastuzumab
- P: pertuzumab
This takes about 18 weeks, followed by a scan or breast ultrasound to assess response.
This treatment aims to shrink or eradicate cancer in the breast and nodes before surgery. HER2-positive cancers often have a strong response to this combination. The combination of trastuzumab and pertuzumab with chemotherapy before surgery is supported for high-risk HER2-positive disease, including node-positive cases. A recent systematic review of dual HER2 blockade supports this approach.
Before treatment, she needs:
- 2D echocardiogram to check heart pumping function
- CBC, kidney and liver tests
- Hepatitis-B screening
- HbA1c and glucose management, as her PET-CT glucose was high
- Ideally, biopsy confirmation and clip placement in the suspicious left axillary node, if this has not already been done
2. Surgery
After completing pre-operative treatment, surgery is done.
The surgeon has proposed:
Left mastectomy + axillary clearance
This may be appropriate, particularly if the axillary node is confirmed positive. In some cases, if there is a very good response, breast-conserving surgery and more limited node surgery can be discussed. This depends on tumor response, breast size, node biopsy result, and the surgeon's assessment.
3. Radiation
Because lymph nodes are suspicious, radiation will likely be advised after surgery. This may treat:
- chest wall after mastectomy
- axillary/supraclavicular nodal region
- internal mammary lymph-node region
4. HER2 treatment after surgery
The post-surgery medicine depends on the surgical pathology:
- If no invasive cancer remains: continue trastuzumab, often with pertuzumab in node-positive disease, to complete about 1 year total of HER2-targeted treatment.
- If invasive cancer remains in breast or lymph nodes: treatment is often changed to T-DM1 injections after surgery, commonly for 14 cycles.
5. Hormone tablets
Because ER and PR are positive, she will likely need endocrine therapy after chemotherapy and surgery. At age 69, this is usually an aromatase-inhibitor tablet such as:
- letrozole
- anastrozole
- exemestane
This is usually taken for at least 5 years. Bone-density monitoring and calcium/vitamin D or bone-protective treatment may be needed because the PET-CT already noted osteopenia.
Bottom line
The cancer is:
Grade-3, HER2-positive, ER/PR-positive invasive ductal carcinoma with suspected regional lymph-node involvement but no distant spread.
A strong standard approach to discuss with the medical oncologist is:
6 cycles of TCHP → surgery → radiation → complete HER2-targeted treatment for one year → hormone tablets for at least 5 years.
The proposed direct mastectomy is not automatically wrong, but given the HER2-positive tumor, size, grade, and suspicious nodes, a medical oncologist review before surgery is important to decide whether treatment should begin with TCHP.
This is a shared conversation. Sign in to Orris to start your own chat.